Ernexa Therapeutics (ERNAW) Accounts Payables (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Accounts Payables data on file, last reported at $1.3 million in Q1 2026.

• Quarterly Accounts Payables rose 1.96% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 1.96% YoY) and the FY2025 annual result came in at $1.1 million, down 34.63% from the prior year.
• Accounts Payables climbed to $1.3 million in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $2.7 million in Q2 2023 to a low of $958000.0 in Q3 2025.
• A 5-year average of $1.5 million and a median of $1.5 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables slumped 59.83% — and 2023, when it jumped 80.99%.
• Tracing ERNAW's Accounts Payables over 5 years: stood at $1.6 million in 2022, then slumped by 34.14% to $1.1 million in 2023, then soared by 61.29% to $1.7 million in 2024, then slumped by 34.63% to $1.1 million in 2025, then climbed by 15.56% to $1.3 million in 2026.
• The last three Accounts Payables figures came in at $1.3 million (Q1 2026), $1.1 million (Q4 2025), and $958000.0 (Q3 2025), per Business Quant data.